regenerative-and-precision-medicine-2016_tracks

9 / 13

Notes:
Page 42
Regenerative & Precision Medicine 2016
December 1-2, 2016
Volume 7, Issue 3(Suppl) J Tissue Sci Eng
ISSN: 2157-7552 JTSE, an open access journal
conferenceseries .com
December 1-2, 2016 | San Antonio, USA
Global Congress on
Tissue Engineering, Regenerative &
Precision Medicine
Carlo R Largiadèr et al., J Tissue Sci Eng 2016, 7:3(Suppl)
Health Care integrated biobanking, an important resource for precision medicine
Carlo R Largiadèr, Tanja K Froehlich and Martin G Fiedler
University of Bern, Switzerland
Biobanks are essential for biomedical research and, more specifically, for the discovery and development of novel diagnostic
biomarkers in the context of personalized medicine. They represent a reservoir for future clinical studies, and thus, accelerate
the development and validation of new biomarkers and therapies, while reducing the costs of clinical research. Despite recent
methodological advances in “omics" technologies, the discovery of new biomarkers has been largely prevented by uncontrolled
variability in the quality among and within existing Biospecimen collections. Therefore, state of the art technological Biobank
infrastructure that enables researchers to meet the quality requirements of liquid samples is an indispensable precondition for the
use of future analytical technologies, such as mass spectrometry. The Inselpital (University Hospital Bern) has implemented for its
Liquid Biobank Bern an infrastructure, whosemajor focus is on sample quality. All pre-analytical processes are fully standardized and
integrated into the clinical routine. Samples are being frozen only one hour after the blood draw with every step in the pre-analytical
process being electronically monitored and documented. Such modern health-care integrated and automated biobanks provide an
important resource of high quality samples for the application of modern omics-technologies in clinical research. In particular, the
ability to document the quality of samples is an important precondition to identify and to account for potential sources of bias that
have led to irreproducible published results during the “omics”-hype.
Biography
Carlo R. Largiadèr is a molecular population geneticist. He is currently vice director of the University Institute of Clinical Chemistry (UKC) at the Inselspital and the
academic head of the Liquid Biobank Bern (LBB). He also heads a research group in Pharmacogenomics and drug metabolism at the UK. His current research
focuses on genetic and non-genetic factors or mechanisms underlying inter-individual variation in drug response with a strong interest in translational aspects.